#Israel #Ramat Gan #Galmed #Colospan #EoCene

Galmed Pharmaceuticals Rebrands as EoCene, Signaling a New Era in Gastrointestinal Innovation

In a strategic transition this September, Galmed Pharmaceuticals Ltd. officially transformed into EoCene Ltd., shedding its previous identity to better reflect its evolving mission in the biopharmaceutical landscape. The company announced that its new trading symbol on the Nasdaq Capital Market will be "EOCN", a change that is set to take effect on September 10, 2026.

Embracing Change

The name 'EoCene', derived from ancient Greek, symbolizes 'the dawn of a new era', which captures the essence of the company's ambition to innovate within the gastrointestinal (GI) disease sector. EoCene aims to develop groundbreaking therapies and technologies that tackle significant unmet medical needs concerning GI illnesses and cancers, marking a substantial shift from its historical focus.

With this rebranding, EoCene emphasizes its intention to harness the potential of its recent acquisition, Colospan Ltd., expanding its portfolio beyond traditional biopharmaceutical responses to include innovative medical devices that can radically change postoperative care.

Focus on Gastrointestinal Health

At the heart of EoCene's new identity is its strategic emphasis on advancing a diversified platform that integrates surgical technologies, therapeutic avenues, and a dedicated focus on gastrointestinal disease management. The acquisition of Colospan has positioned the company to not only expand its product lines but also accelerate the development of solutions that respond to anastomotic leak complications and related burdens after colorectal surgeries.

As stated by Allen Baharaff, President and CEO, this change is not merely cosmetic; it signifies a pivotal moment: "The introduction of the Eocene name marks an important new chapter for our company. As we continue to advance our business, we are bringing together scientific, clinical, and technological capabilities that we believe position us to address meaningful opportunities across gastrointestinal health."

The newly branded EoCene will leverage both its clinical expertise and Colospan's proprietary device technology to drive significant advances in GI disease management. This will encompass myriad areas, creating synergies that enhance patient outcomes, while continuing to pursue its Biopharmaceutical development path.

Financial Restructuring and Compliance

In conjunction with the corporate rebranding, EoCene also announced the termination of its Standby Equity Purchase Agreement (SEPA) with Yorkville, effective September 8, 2026. This SEPA allowed access to potential equity funding but was concluded as part of EoCene's strategic repositioning. As of the termination date, approximately $7.3 million had been raised via this arrangement, providing a solid cash foundation for future operations.

Additionally, in recent developments, EoCene has regained compliance with the Nasdaq Listing Rule 5550(a)(2), ensuring that its shares will continue to be traded without interruption under the new ticker symbol. Importantly, shareholders are informed that the changes do not affect their ownership interests in the company.

Looking to the Future

EoCene aims to build a diversified portfolio acrossmedical devices, therapeutic innovations, and enabling technologies designed specifically for GI health challenges. By combining its internal research with strategic acquisitions and partnerships, the company hopes to create long-term value not only for its shareholders but also for patients and healthcare providers alike.

Overall, this evolution from Galmed Pharmaceuticals to EoCene showcases a commitment to increasing the focus on tackling GI diseases through innovative means while forging pathways toward potential commercial revenue sooner than traditional drug development might allow. Moving forward, EoCene is poised to redefine its role within the healthcare sphere as a comprehensive GI-focused entity, integrating cutting-edge therapies and solution-driven approaches, positioning itself prominently in a critical medical domain.

• ---

For more information about EoCene and its offerings, visit www.EOCN.com and explore the groundbreaking advancements they are bringing to GI health care practices.